Rothschild Investment LLC Acquires Shares of 210 Cencora, Inc. (NYSE:COR)

Rothschild Investment LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 210 shares of the company’s stock, valued at approximately $47,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in COR. Vanguard Group Inc. acquired a new stake in shares of Cencora in the fourth quarter valued at about $4,212,508,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Cencora in the first quarter valued at about $2,183,619,000. JPMorgan Chase & Co. acquired a new stake in shares of Cencora in the first quarter valued at about $1,199,695,000. Boston Partners acquired a new stake in shares of Cencora in the first quarter valued at about $1,001,269,000. Finally, Capital Research Global Investors acquired a new stake in shares of Cencora in the first quarter valued at about $650,424,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is currently owned by company insiders.

Cencora Price Performance

Shares of COR opened at $236.29 on Friday. Cencora, Inc. has a 1-year low of $171.65 and a 1-year high of $247.66. The stock has a market cap of $47.13 billion, a PE ratio of 25.85, a P/E/G ratio of 1.57 and a beta of 0.45. The firm has a 50-day simple moving average of $232.08 and a two-hundred day simple moving average of $233.16. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. During the same period last year, the business earned $2.92 earnings per share. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. As a group, analysts forecast that Cencora, Inc. will post 13.61 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Friday, August 9th. Cencora’s payout ratio is 22.32%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Robert W. Baird increased their target price on shares of Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Leerink Partners restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and an average target price of $258.63.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.